These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 20798382)

  • 1. SCH 602539, a protease-activated receptor-1 antagonist, inhibits thrombosis alone and in combination with cangrelor in a Folts model of arterial thrombosis in cynomolgus monkeys.
    Chintala M; Strony J; Yang B; Kurowski S; Li Q
    Arterioscler Thromb Vasc Biol; 2010 Nov; 30(11):2143-9. PubMed ID: 20798382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BF061, a novel antiplatelet and antithrombotic agent targeting P2Y₁₂ receptor and phosphodiesterase.
    Hu L; Fan Z; Du H; Ni R; Zhang S; Yin K; Ye J; Zhang Y; Wei X; Zhang X; Gross PL; Kunapuli SP; Ding Z
    Thromb Haemost; 2011 Dec; 106(6):1203-14. PubMed ID: 21946947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists.
    van Giezen JJ; Humphries RG
    Semin Thromb Hemost; 2005 Apr; 31(2):195-204. PubMed ID: 15852223
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial.
    Greenbaum AB; Ohman EM; Gibson CM; Borzak S; Stebbins AL; Lu M; Le May MR; Stankowski JE; Emanuelsson H; Weaver WD
    Am Heart J; 2007 Oct; 154(4):702-9. PubMed ID: 17892995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cangrelor for the management and prevention of arterial thrombosis.
    Storey RF; Sinha A
    Expert Rev Cardiovasc Ther; 2016 Sep; 14(9):991-9. PubMed ID: 27362653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease.
    Serebruany VL; Kogushi M; Dastros-Pitei D; Flather M; Bhatt DL
    Thromb Haemost; 2009 Jul; 102(1):111-9. PubMed ID: 19572075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P2Y receptor antagonists in thrombosis.
    Boeynaems JM; van Giezen H; Savi P; Herbert JM
    Curr Opin Investig Drugs; 2005 Mar; 6(3):275-82. PubMed ID: 15816504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical overview of promising nonthienopyridine antiplatelet agents.
    Angiolillo DJ; Guzman LA
    Am Heart J; 2008 Aug; 156(2 Suppl):S23-8. PubMed ID: 18657683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SCH-530348, a thrombin receptor (PAR-1) antagonist for the prevention and treatment of atherothrombosis.
    Oestreich J
    Curr Opin Investig Drugs; 2009 Sep; 10(9):988-96. PubMed ID: 19705342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cangrelor: a review on pharmacology and clinical trial development.
    Franchi F; Rollini F; Muñiz-Lozano A; Cho JR; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2013 Oct; 11(10):1279-91. PubMed ID: 24138516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in antiplatelet therapy.
    Michelson AD
    Hematology Am Soc Hematol Educ Program; 2011; 2011():62-9. PubMed ID: 22160013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
    Penz SM; Reininger AJ; Toth O; Deckmyn H; Brandl R; Siess W
    Thromb Haemost; 2007 Mar; 97(3):435-43. PubMed ID: 17334511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet P2 receptors: old and new targets for antithrombotic drugs.
    Cattaneo M
    Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):45-55. PubMed ID: 17187456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cangrelor: a review on its mechanism of action and clinical development.
    Ferreiro JL; Ueno M; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2009 Oct; 7(10):1195-201. PubMed ID: 19814662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model.
    Huang J; Driscoll EM; Gonzales ML; Park AM; Lucchesi BR
    J Pharmacol Exp Ther; 2000 Nov; 295(2):492-9. PubMed ID: 11046080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cangrelor: a novel P2Y12 receptor antagonist.
    Norgard NB
    Expert Opin Investig Drugs; 2009 Aug; 18(8):1219-30. PubMed ID: 19604122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a vorapaxar analog with increased aqueous solubility.
    Xia Y; Chackalamannil S; Greenlee WJ; Wang Y; Hu Z; Root Y; Wong J; Kong J; Ahn HS; Boykow G; Hsieh Y; Kurowski S; Chintala M
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6676-9. PubMed ID: 20888225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cangrelor for treatment of coronary thrombosis.
    Fugate SE; Cudd LA
    Ann Pharmacother; 2006 May; 40(5):925-30. PubMed ID: 16595568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates.
    Derian CK; Damiano BP; Addo MF; Darrow AL; D'Andrea MR; Nedelman M; Zhang HC; Maryanoff BE; Andrade-Gordon P
    J Pharmacol Exp Ther; 2003 Feb; 304(2):855-61. PubMed ID: 12538843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of a novel platelet nitric oxide donor (LA816), aspirin, clopidogrel, and combined therapy in inhibiting flow- and lesion-dependent thrombosis in the porcine ex vivo model.
    Vilahur G; Segalés E; Salas E; Badimon L
    Circulation; 2004 Sep; 110(12):1686-93. PubMed ID: 15381660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.